CompletedNCT00916552
Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Depression and Bipolarity
Medication studyAges 18–65Denmark
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- CopenhagenSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateSeptember 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 83
- Sponsor
- Lars Vedel Kessing, professor, MD, DMSc.
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Denmark
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00916552
- Official title
Show the full official title
The Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Patients With Treatment Resistant Depression and in Patients With Remitted Bipolar Disorder - a Proof of Concept Study
Recruitment & locations
CompletedCopenhagen
Questions about this study
Who is behind this study?
The study sponsor is Lars Vedel Kessing, professor, MD, DMSc.
Did this study involve medication?
Yes. The study involved medication, including Erythropoietin.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
Effects of Erythropoietin for Cognitive Side-effects of ECT
Effects of Erythropoietin on Cognition and Neural Activity in Mood Disorders